Sixteen years after the success of Project START for HIV risk reduction, we still don't know what works best for helping people with HIV stay in care after prison.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Health care providers often believe stereotypes that PWID are irresponsible and won't adhere to PrEP, according to data presented at the 2019 National HIV Prevention Conference.
Undetectable equals untransmittable (U=U) has improved HIV prevention and tackled stigma, but there are still a few questions to answer.
Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.
As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.
A leading researcher at the Centers for Disease Control and Prevention addressed community concerns that surveillance data will be used to put people in prison under HIV criminalization laws.
'Drug Users Are People Too': Addressing Opioid Addiction, Chemsex, Alcoholism, and Smoking Among People Living With HIV
A CROI 2019 symposium demonstrated the need for continued research and programs that address substance use and its impact on people living with HIV.
"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?